FDA Scientists link transfused UVB irradiated platelets with acute lung injury
![Pharmaceutical Biotechnology for Non-Biotechnologists](files/eca/userImages/training.img/Z-ECA-Pharmaceutical-Biotechnology-Non-Biotechnologists.jpg)
Recommendation
9/10 October 2024
Berlin, Germany
An Overview and Insight in Pharmaceutical Biotechnology
With a mouse model, scienists demonstrated a link between transfused UVB irradiated platelets and acute lung injury. The scientists at the U.S. Food and Drug Administration (FDA) reported that studies performed in animals provide a proof of a concept that transfused UV-light damaged PLTs can mediate lung injury. These studies suggest that patients whose lungs are already inflamed by an underlying condition or cause, could potentially suffer further lung damage if they receive a transfusion of platelets that were exposed to ultraviolet B (UVB) light.
The scientists at FDA's Center for Biologics Evaluation and Research (CBER) conducted the study in response to an observation in a clinical trial where some patients who were transfused with platelets treated with UV light and a photosensitizing chemical to reduce the presence of pathogens (e.g., viruses and bacteria), appeared to be more likely to develop sudden respiratory distress.
The scientific article "Ultraviolet B light-exposed human platelets mediate acute lung injury in a two-event mouse model of transfusion" was published at Transfusion, 2011, 51:2343-2357 by Monique P. Gelderman, Xuan Chi, Li Zhi, and Jaroslav G. Vostal, Laboratory of Cellular Hematology, Division of Hematology, Office of Blood Research and Review, Center for Biologics Evaluation and Research, Food and Drug Administration, Rockville, MD.
More details can be found in the report entitled "A mouse model demonstrates a link between transfused UVB irradiated platelets and acute lung injury".
Related GMP News
29.05.2024New FDA Draft Guideline regarding the Use of Human- and Animal-derived Materials
22.05.2024New FDA Draft Guideline regarding Safety Testing of human allogeneic Cells
07.05.2024Final Approval of SoHO Regulation
07.05.2024FDA Warning Letter to a Biotechnology Company in China
07.05.2024Update of Guideline on Epidemiological Data
05.03.2024FDA Warning Letter on misbranded and unapproved Drugs